Drugs / umbilical cord blood CD19-BCMA CAR-T cells
umbilical cord blood CD19-BCMA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06947473 | Mar → Jul 2026 overdue | Sjogren syndrome, lupus nephritis, systemic sclerosis | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | umbilical cord blood CD19-BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06947473 ↗ |
| Modality | Cell therapy | “umbilical cord blood CD19-BCMA CAR T cell therapy” NCT06947473 ↗ |